“Dasatinib tyrosine kinase inhibitor as second and third line therapy in chronic myeloid leukemia: outcome of a Nepalese study” (2018) Journal of Patan Academy of Health Sciences, 5(1), pp. 47–56. doi:10.3126/jpahs.v5i1.24042.